Comparative Pharmacology
Head-to-head clinical analysis: BRISTAMYCIN versus ERY TAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAMYCIN versus ERY TAB.
BRISTAMYCIN vs ERY-TAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRISTAMYCIN is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
500 mg intravenously every 6 hours. Infuse over 60 minutes.
250-500 mg orally every 6 hours or 333-666 mg every 8 hours. Maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 6–8 hours (prolonged to 20–40 hours in severe renal impairment; dose adjustment required for CrCl <30 mL/min).
The terminal elimination half-life of erythromycin base is approximately 1.5-2 hours in patients with normal renal function. In patients with end-stage renal disease, the half-life may be prolonged to 4-6 hours. The half-life is not significantly altered in hepatic impairment, but accumulation can occur with severe liver disease.
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5% as unchanged drug and metabolites.
Erythromycin is primarily excreted in bile as active drug and metabolites, with approximately 12-15% of an administered dose excreted unchanged in urine. Fecal elimination accounts for about 30-60% of the dose, largely due to biliary excretion.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic